Cargando…

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis

BACKGROUND: Concurrent cisplatin with radiotherapy (CRT) or concurrent cetuximab with radiotherapy (BRT) improves outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) compared with radiotherapy alone. Nevertheless, a detailed comparison between CRT and BRT in locally advanced H...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Wen-Hua, Sun, Wei, Long, Guo-Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478598/
https://www.ncbi.nlm.nih.gov/pubmed/32899005
http://dx.doi.org/10.1097/MD.0000000000021785
_version_ 1783580088238866432
author Tang, Wen-Hua
Sun, Wei
Long, Guo-Xian
author_facet Tang, Wen-Hua
Sun, Wei
Long, Guo-Xian
author_sort Tang, Wen-Hua
collection PubMed
description BACKGROUND: Concurrent cisplatin with radiotherapy (CRT) or concurrent cetuximab with radiotherapy (BRT) improves outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) compared with radiotherapy alone. Nevertheless, a detailed comparison between CRT and BRT in locally advanced HNSCC is required due to inconclusive results. METHODS: A comprehensive literature search was conducted on PubMed, Web of Science, Cochrane databases, and EMBASE. Studies that evaluated CRT vs BRT in locally advanced HNSCC were included. The primary outcome that was overall survival (OS), whereas the secondary outcomes were progression-free survival (PFS), locoregional control (LRC), and distant metastasis-free survival (DMFS). Pooled hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were used to evaluate prognosis. All the analyses were performed using Stata Statistical Software 12.0. RESULTS: Twenty-three studies, with a total of 8701 patients, were considered eligible and included in this meta-analysis. Our results revealed that patients treated with CRT had longer OS (HR = 0.51, 95%CI, 0.41–0.64, P < .001), PFS (HR = 0.37, 95%CI, 0.23–0.60, P < .001), LRC (HR = 0.46, 95%CI, 0.37–0.57, P < .001), and DMFS (HR = 0.56, 95%CI, 0.40–0.77, P < .001) than those treated with BRT. Furthermore, the results of the subgroup analyses were consistent with the primary analysis. CONCLUSIONS: CRT has a better OS, PFS, LRC, and DMFS than BRT in locally advanced HNSCC, and should be the preferred treatment for patients with the disease.
format Online
Article
Text
id pubmed-7478598
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-74785982020-09-24 Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis Tang, Wen-Hua Sun, Wei Long, Guo-Xian Medicine (Baltimore) 5700 BACKGROUND: Concurrent cisplatin with radiotherapy (CRT) or concurrent cetuximab with radiotherapy (BRT) improves outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) compared with radiotherapy alone. Nevertheless, a detailed comparison between CRT and BRT in locally advanced HNSCC is required due to inconclusive results. METHODS: A comprehensive literature search was conducted on PubMed, Web of Science, Cochrane databases, and EMBASE. Studies that evaluated CRT vs BRT in locally advanced HNSCC were included. The primary outcome that was overall survival (OS), whereas the secondary outcomes were progression-free survival (PFS), locoregional control (LRC), and distant metastasis-free survival (DMFS). Pooled hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were used to evaluate prognosis. All the analyses were performed using Stata Statistical Software 12.0. RESULTS: Twenty-three studies, with a total of 8701 patients, were considered eligible and included in this meta-analysis. Our results revealed that patients treated with CRT had longer OS (HR = 0.51, 95%CI, 0.41–0.64, P < .001), PFS (HR = 0.37, 95%CI, 0.23–0.60, P < .001), LRC (HR = 0.46, 95%CI, 0.37–0.57, P < .001), and DMFS (HR = 0.56, 95%CI, 0.40–0.77, P < .001) than those treated with BRT. Furthermore, the results of the subgroup analyses were consistent with the primary analysis. CONCLUSIONS: CRT has a better OS, PFS, LRC, and DMFS than BRT in locally advanced HNSCC, and should be the preferred treatment for patients with the disease. Lippincott Williams & Wilkins 2020-09-04 /pmc/articles/PMC7478598/ /pubmed/32899005 http://dx.doi.org/10.1097/MD.0000000000021785 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5700
Tang, Wen-Hua
Sun, Wei
Long, Guo-Xian
Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
title Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
title_full Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
title_fullStr Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
title_full_unstemmed Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
title_short Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
title_sort concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: a meta-analysis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478598/
https://www.ncbi.nlm.nih.gov/pubmed/32899005
http://dx.doi.org/10.1097/MD.0000000000021785
work_keys_str_mv AT tangwenhua concurrentcisplatinorcetuximabwithradiotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaametaanalysis
AT sunwei concurrentcisplatinorcetuximabwithradiotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaametaanalysis
AT longguoxian concurrentcisplatinorcetuximabwithradiotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaametaanalysis